PERCHERON THERAPEUTICS LIMITED — Director's Dealing 2012

Jul 23, 2012

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Amended Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Name of Entity: Antisense Therapeutics Limited (ASX:ANP) ABN: 41 095 060 745

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director: Mr Mark Diamond Date of Last Notice: 24[rh] July 2012

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

disclosed in this part.
Direct or indirect interest		Direct
Nature of indirect interest(including registered holder)Note: Provide details of the circumstances givingrise to the relevant interest.		-
Date of change		24thJuly 2012
No. of securities held prior tochange		SharesOptionsDirect3,439,818Unlisted Options exp.30/7/18@Nil3,000,000ANPO Options exp. 31/7/12@$0.011812,460Unlisted Options exp.27/6/13@$0.0720(7.2 cents)2,000,000Indirect--Total3,439,8185,812,460
			Shares	Options
		Direct	3,439,818
		Unlisted Options exp.30/7/18@Nil		3,000,000
		ANPO Options exp. 31/7/12@$0.011		812,460
		Unlisted Options exp.27/6/13@$0.0720(7.2 cents)		2,000,000
		Indirect	-	-
		Total	3,439,818	5,812,460
Class		Ordinary Shares
Number acquired		SharesOptionsDirecta)3,000,000b) 812,460-Indirect--Total3,812,460-

• See chapter 19 for defined terms.

Appendix 3Y Page 1

11/3/2002

Appendix 3Y Change of Director’s Interest Notice

Number disposed				Optionsa)3,000,000b) 812,460-3,812,460
			Shares	Options
		Direct	-	a)3,000,000b) 812,460
		Indirect	-	-
		Total	-	3,812,460
Value/ConsiderationNote: If consideration is non-cash, provide detailsand estimated valuation		a) Nil cents per share as per 2008 Employee Option Planb)1.1cents pershare
No. of securities held after change				Options2,000,000-2,000,000
			Shares	Options
		Direct	7,252,278
		Unlisted Options exp. 7/6/13@$0.0720(7.2 cents)		2,000,000
		Indirect	-	-
		Total	7,252,278	2,000,000
Nature of changeExample:on-markettrade,off-market trade,exercise of options, issue of securities underdividend reinvestment plan, participation in buy-back		Exercise of Options

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Note: In the case of a company, interests which come withindisclosed in this part.	paragraph (ii) of the definition of “notifiable interest of a director” should be
Detail of contract	N/A
Nature of interest	N/A
Name of registered holder(if issued securities)	N/A
Date of change	N/A
No. and class of securities towhich interest related prior tochangeNote: Details are only required for a contract in relationto which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/ConsiderationNote: If consideration is non-cash, provide details and anestimated valuation	N/A
Interest after change	N/A

Part 3 - +Closed Period

Were the interests in the securities or contracts detailed above traded No during a +closed period where prior written clearance was required? If so, was prior written clearance provided to allow the trade to N/A proceed during this period? If prior written clearance was provided on what date was this N/A provided?

==> picture [45 x 27] intentionally omitted <==

The CFO Solution

24.07.2012

• See chapter 19 for defined terms.

Appendix 3Y Page 2

11/3/2002